Cargando…

Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway

BACKGROUND: Resveratrol is reported to inhibit the growth of prostate, which is characteristic of benign prostatic hyperplasia (BPH) condition. However, the mechanism remains unclear. This study aimed to identify the effects and probable mechanism of resveratrol on BPH. METHODS: We used the BPH epit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chao, Hu, Wan-Li, Lu, Meng-Xin, Xiao, Guan-Fa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714439/ https://www.ncbi.nlm.nih.gov/pubmed/31464618 http://dx.doi.org/10.1186/s12906-019-2648-8

Ejemplares similares

Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH)
por: Sciacqua, L. V., et al.
Publicado: (2023)

Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with Trichomonas vaginalis
por: Kim, Sang-Su, et al.
Publicado: (2016)

Bladder stone secondary to prostatic urethral lift (PUL) for benign prostatic hyperplasia (BPH)
por: Kang, JiHun
Publicado: (2021)

Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)
por: Cambio, Angelo J, et al.
Publicado: (2007)

What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
por: Foo, Keong Tatt
Publicado: (2019)

Resveratrol Attenuates the Proliferation of Prostatic Stromal Cells in Benign Prostatic Hyperplasia by Regulating Cell Cycle Progression, Apoptosis, Signaling Pathways, BPH Markers, and NF-κB Activity
por: Jang, Jowon, et al.
Publicado: (2021)

Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events
por: Ko, Young Hwii, et al.
Publicado: (2010)

Early Experience with Laparoscopic Retropubic Simple Prostatectomy in Patients with Voluminous Benign Prostatic Hyperplasia (BPH)
por: Yun, Han Ki, et al.
Publicado: (2010)

Assessing the Influence of Benign Prostatic Hyperplasia (BPH) on Erectile Dysfunction (ED) among patients in Poland
por: Dutkiewicz, Sławomir, et al.
Publicado: (2012)

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
por: Hellwege, Jacklyn N., et al.
Publicado: (2019)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS‐BPH)
por: Chen, Z.P., et al.
Publicado: (2018)

Real‐world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain
por: María Molero, José, et al.
Publicado: (2020)

Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)
por: Saponaro, Miriam, et al.
Publicado: (2020)

Therapeutic potential of pomegranate juice-derived nanovesicles in nude mouse benign prostatic hyperplasia (BPH) xenograft model
por: Sreekumar, Amritha, et al.
Publicado: (2023)

Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats
por: Sasidharan, Shan, et al.
Publicado: (2022)

1-year cost-utility analysis of prostate artery embolization (PAE) versus transurethral resection of the prostate (TURP) in benign prostatic hyperplasia (BPH)
por: Patel, Nikisha, et al.
Publicado: (2021)

Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH
por: Arias‐Chávez, David Julian, et al.
Publicado: (2023)

Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH
por: Saito, Motoaki, et al.
Publicado: (2014)

Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys
por: Cinislioglu, Ahmet Emre, et al.
Publicado: (2022)

Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study
por: Zhang, Weiyu, et al.
Publicado: (2019)

Ultrasound-guided SoracteLite™ transperineal laser ablation (TPLA) of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH): a prospective single-center experience
por: Laganà, Antonino, et al.
Publicado: (2023)

Long-term survival of stage A prostate carcinoma, atypical hyperplasia/adenosis and BPH.
por: Brawn, P. N., et al.
Publicado: (1994)

Benign Prostatic Hyperplasia
Publicado: (2015)

Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation
por: Zhang, Bo, et al.
Publicado: (2021)

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
por: Woo, Henry H., et al.
Publicado: (2022)

Selective Transurethral Resection of the Prostate Combined with Transurethral Incision of the Bladder Neck for Bladder Outlet Obstruction in Patients with Small Volume Benign Prostate Hyperplasia (BPH): A Prospective Randomized Study
por: Li, Xin, et al.
Publicado: (2013)

Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019)

BPH and prostate cancer risk
por: Miah, Saiful, et al.
Publicado: (2014)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

LncRNA DIO3OS regulated by TGF-β1 and resveratrol enhances epithelial mesenchymal transition of benign prostatic hyperplasia epithelial cells and proliferation of prostate stromal cells
por: Chen, Yanbo, et al.
Publicado: (2021)

Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
por: Cindolo, Luca, et al.
Publicado: (2015)

Prostate epithelial stem cells are resistant to apoptosis after α1-antagonist treatment. The impact for BPH patients
por: Bajek, Anna, et al.
Publicado: (2011)

Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis
por: Jin, Bo-Ram, et al.
Publicado: (2020)

Androgen Receptor Expression in Epithelial and Stromal Cells of Prostatic Carcinoma and Benign Prostatic Hyperplasia
por: Filipovski, Vanja, et al.
Publicado: (2017)

Molecular Breeding of Rice Restorer Lines and Hybrids for Brown Planthopper (BPH) Resistance Using the Bph14 and Bph15 Genes
por: Wang, Hongbo, et al.
Publicado: (2016)

A two-week, double-blind, placebo-controlled trial of Viola odorata, Echium amoenum and Physalis alkekengi mixture in symptomatic benign prostate hyperplasia (BPH) men
por: Beiraghdar, Fatemeh, et al.
Publicado: (2017)

Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS)
por: Ratajczak, Weronika, et al.
Publicado: (2021)

Making shared decisions with older men selecting treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH): a pilot randomized trial
por: Ngu, Haidee, et al.
Publicado: (2022)

Resveratrol Induces Growth Arrest and Apoptosis through Activation of FOXO Transcription Factors in Prostate Cancer Cells
por: Chen, Qinghe, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_gchd32nbvu1cf5gv13bdfpp4vh